Table 6.
Number and percentages of patients who underwent a total hip replacement in the safety population (n=398)
| Patients who underwent THR | Placebo (209) | ASU-E (189) | Total (398) | p (Fisher) |
|---|---|---|---|---|
| Between baseline and month 42 (n (%)) | 39/209* (18.7) | 44/189* (23.3) | 83/398 (20.9) | 0.269 |
| Baseline JSW<2.5 mm (n (%)) | 27/77 (35.1) | 27/67 (40.3) | 54/144 (37.5) | 0.605 |
| Baseline JSW≥2.5 mm (n (%)) | 12/130 (9.2) | 17/121 (14.0) | 29/251 (11.6) | 0.244 |
| Within 6 months after the end of the trial at patient level (n (%)) | 35/209* (16.7) | 38/189* (20.1) | 73/398 (18.3) | 0.437 |
| Baseline JSW<2.5 mm (n (%)) | 23/77 (29.9) | 24/67 (35.8) | 47/144 (32.6) | 0.480 |
| Baseline JSW≥2.5 mm (n (%)) | 12/130 (9.2) | 14/121 (11.6) | 26/251 (10.4) | 0.679 |
*Three patients had no target hip radiographs at baseline (two in the placebo group and one in the ASU-E group).
ASU-E, avocado–soybean unsaponifiable—Expanscience; JSW, joint space width; THR, total hip replacement.